Purified Membrane Proteins
CALIXAR’s B-lymphocyte antigen CD20 helps to identiy validated target of monoclonal antibodies in the treatment of all B cell lymphomas and leukemias as well as autoimmune diseases.
B-lymphocyte antigen Cd20 is a powerful clinically-validated therapeutic target of monoclonal antibodies especially in the treatment of malignancies and auto-immune disorders.
This class A GPCR is is highly expressed on the cell surface of B-cell lymphocytes and is a membrane marker of malignant B
Target name: B-lymphocyte antigen CD20 (CD20)
Uniprot Accession: P11836
Origin: Human (Homo sapiens)
Class: Class A GPCR
Sequence: Full-length, wildtype sequence, with a C-terminus TEV protease cleavage site, FlagTag and a 10xHis-tag
Affinity Tag: Flag/His (both C-terminal)
Catalogue number: PP5
Theor. MW: 36,8kDa
Shipment temperature: Dry Ice
Storage conditions: Store at -80°C
Expression system: HEK (baculovirus)
Purification: Immobilized Metal Affinity Chromatography
Activity: Confirmed by radiobinding assay
Concentration: Up to 5mg/ml
Sample buffer: 1X TBS, 150mM NaCl, 10% glycerol, 5 mM Calx7gluk (2CMC)
Available quantity: From 10µg up to mg scale
Ships in 7 business days
Why choose us?
Cluster of Differenciation 20 CALIXAR’s B-lymphocyte antigen CD20 facilitates reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery corresponding to this specific target.
Unlike CALIXAR’s Adenosine receptor A2A, other alternative methods result in an adenosine receptor that becomes mutated and truncated (96 amino-acids truncation in the C-terminus). Additionally, this mutated version becomes locked within an antagonist conformation.
As with all GPCRs, the Cluster of Differenciation 20 is an unstable target and is difficult to produce natively with conventional approaches. Previously, Adenosine receptor A2A could only be locked in one specific conformation (e.g. antagonist) and were only ever prepared in a solution that inherently could not be pure, nor native (truncated, mutated) and without PTMs. A2AR’s have only ever been inherently unstable, but not anymore.
Today, CALIXAR’s Adenosine receptor A2A is able to bind to agonists, antagonists, as well as allosteric modulators (Igonet S. et al., 2018, Scientific Reports). Our Adenosine receptor A2A also maintain its structural and functional integrity and is purified and stabilized to full length and wild-type (native) proteins.
CALIXAR’s CD20 membrane protein opening the way in the discovery and optimization of next-generation therapeutic antibodies.
CALIXAR’s Adenosine receptor A2A is the first native full-length and functional target on the market. Other existing A2AR targets are either mutated or truncated. Our A2AR protein is produced in a eukaryotic system with the proper post-translational modifications (glycosylation).
CALIXAR’s Adenosine receptor A2A is high-quality membrane proteins used for (bio)drug discovery and are adapted for use in pharmaceutical, biotechnology companies, and as well as for academic teams that are involved in the life science fields.
Igonet S et al. 2018
Discovery on Target
Jawhari A. Boston, 2015
Desuzinges Mandon E. et al. 2017